April 30, 2020 / 6:36 AM / a month ago

BRIEF-Medivir Receives Positive Opinion On Orphan Medicinal Drug Designation By The European Medicines Agency For Miv-818

April 30 (Reuters) - Medivir AB:

* MEDIVIR RECEIVES POSITIVE OPINION ON ORPHAN MEDICINAL DRUG DESIGNATION BY THE EUROPEAN MEDICINES AGENCY FOR MIV-818

* MEDIVIR - RECEIVED POSITIVE OPINION FROM COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ON ORPHAN MEDICINAL PRODUCT DESIGNATION IN EU FOR MIV-818

* MEDIVIR - MIV-818 FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), MOST COMMON TYPE OF PRIMARY LIVER CANCER. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below